Core Viewpoint - Profound Medical Corp. announced a registered direct offering of 5,142,857 common shares at $7.00 per share, aiming for gross proceeds of up to $40 million, including a subsequent private placement of up to 571,428 shares at the same price [1][3][6] Group 1: Offering Details - The registered direct offering is structured as an equity investment with no warrant coverage, led by healthcare-dedicated investors [2] - Gross proceeds from the offering are expected to be approximately $36 million before deducting fees and expenses [3] - The private placement aims for up to $4 million in gross proceeds, with shares subject to a four-month hold period [6] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for sales and marketing expansion, working capital, research and development, strategic transactions, and general corporate purposes [3] Group 3: Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on AI-powered, MRI-guided therapies for tissue ablation [7] - The company is commercializing TULSA-PRO, a technology for treating various prostate conditions, which is incision-free and has a quick recovery time [8] - Profound is also developing Sonalleve, a platform for treating uterine fibroids and other conditions, with approvals in multiple jurisdictions [9]